沙库巴曲缬沙坦钠联合卡维地洛在老年慢性心力衰竭患者中的应用效果OA

Objective:To explore the application effect of Sacubitril Valsartan Sodium combined with Carvedilol in elderly patients with chronic heart failure(CHF).Method:A total of 80 elderly patients with CHF who admitted to Chongqing Wansheng Economic and Technological Development Zone Traditional Chinese Medicine Hospital from August 2022 to August 2023 were selected as the research objects,they were divided into the control group(n=40)and the observation group(n=40)according to the random number table method.The control group was treated with Carvedilol Tablets,while the observation group was treated with Sacubitril Valsartan Sodium Tablets on the basis of the control group.The clinical efficacy,serological indexes[N-terminal B-type pronatriuretic peptide(NT-proBNP),growth differentiation factor-15(GDF-15),soluble intercellular adhesion rnolecule-1(sICAM-1)],vital signs[heart rate(HR),diastolic blood pressure(DBP),systolic blood pressure(SBP)],adverse reactions and quality of life were compared between two groups.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the serological indexes,vital signs and Minnesota living with heart failure questionnaire(MLHFQ)scores between two groups(P>0.05);after treatment,the levels of GDF-15,NT-proBNP,sICAM-1,SBP,DBP,HR and MLHFQ scores in two groups were lower than those before treatment,and those in the observation group were lower than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Sacubitril Valsartan Sodium combined with Carvedilol is effective in the treatment of elderly patients with CHF,which can effectively regulate serological indicators and vital signs,with high safety and quality of life.